A controlled trial of fluvoxamine in obsessive-compulsive disorder: implications for a serotonergic theory.
Thirty-eight patients with primary obsessive-compulsive disorder participated in a 10-week, double-blind, placebo-controlled trial of the potent, selective serotonin reuptake inhibitor fluvoxamine. Fluvoxamine was significantly better than placebo on two of three measures of improvement in obsessive-compulsive symptoms. The authors also compared studies of the serotonergic agents fluvoxamine, sertraline, fluoxetine, and clomipramine and found that a greater effect size was associated with less serotonergic specificity and that some ability to affect other neurotransmitter systems may be a necessary but not sufficient requirement for antiobsessional activity. These data lend only partial support to a serotonin hypothesis of obsessive-compulsive disorder.
Jenike
M A
MA
Harvard Medical School, Boston, MA.
Hyman
S
S
Baer
L
L
Holland
A
A
Minichiello
W E
WE
Buttolph
L
L
Summergrad
P
P
Seymour
R
R
Ricciardi
J
J
D015057:1-Naphthylamine / Q000031:analogs & derivatives / Q000627:therapeutic use; D000328:Adult; D000553:Ambulatory Care; D002986:Clinical Trials as Topic; D002997:Clomipramine / Q000627:therapeutic use; D004311:Double-Blind Method; D005260:Female; D005473:Fluoxetine / Q000627:therapeutic use; D016666:Fluvoxamine; D006801:Humans; D008297:Male; D015201:Meta-Analysis as Topic; D009771:Obsessive-Compulsive Disorder / Q000188:drug therapy* / Q000503:physiopathology / Q000523:psychology; D010091:Oximes / Q000627:therapeutic use*; D010919:Placebos; D011569:Psychiatric Status Rating Scales; D012701:Serotonin / Q000502:physiology; D012702:Serotonin Antagonists / Q000627:therapeutic use*; D020280:Sertraline
D010091:Oximes; D010919:Placebos; D012702:Serotonin Antagonists; D005473:Fluoxetine; D012701:Serotonin; D015057:1-Naphthylamine; D002997:Clomipramine; D016666:Fluvoxamine; D020280:Sertraline